ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
January 08 2009 - 7:30AM
PR Newswire (US)
Webcast Presentation Scheduled for Wednesday, January 14, 2009 at
9:30 a.m. PT BROOMFIELD, Colo. and SAN CARLOS, Calif., Jan. 8
/PRNewswire-FirstCall/ -- ARCA biopharma, Inc., a biopharmaceutical
company developing genetically-targeted therapies for heart failure
and other cardiovascular diseases, and Nuvelo, Inc. (NASDAQ:NUVO)
today announced that Richard Brewer, ARCA's president and chief
executive officer, will present at the 27th Annual JPMorgan
Healthcare Conference on Wednesday, January 14, 2009, at 9:30.a.m.
PT in San Francisco. ARCA biopharma and Nuvelo, Inc. announced on
September 25, 2008 that they have entered into a definitive merger
agreement, expected to create a cardiovascular-focused, late-stage
biotechnology company. The presentation will discuss the assets of
both companies, including ARCA's lead product Gencaro(TM)
(bucindolol hydrochloride), a near-term commercial opportunity, as
well as Nuvelo's mid-stage pipeline asset, novel short-acting
anticoagulant NU172. In September 2008, the FDA formally accepted
for filing ARCA's New Drug Application for Gencaro as a potential
treatment for chronic heart failure. In accordance with the
Prescription Drug User Fee Act (PDUFA), the FDA's goal is to
complete and review all materials regarding Gencaro by May 31,
2009. The presentation will also discuss the structure and
strategic plan of the combined company, pending the closing of the
merger. A live audio webcast of the presentation will be available
online via the ARCA biopharma website at
http://www.arcabiopharma.com/ or the Investor Relations portion of
Nuvelo's website at http://www.nuvelo.com/. About ARCA biopharma
ARCA biopharma, Inc. is a privately held company focused on
developing and commercializing genetically targeted therapies for
heart failure and other cardiovascular diseases. The Company's lead
product candidate, Gencaro(TM) (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for heart failure and other
indications. ARCA has identified common genetic variations that it
believes predict individual patient response to Gencaro. The New
Drug Application for approval of Gencaro for the indication of
chronic heart failure, including the proposed brand name, is
currently under review by the U.S. Food and Drug Administration.
The companion genetic test for Gencaro is in development by ARCA's
partner, Laboratory Corporation of America. For more information
please visit http://www.arcabiopharma.com/. About Nuvelo Nuvelo,
Inc. is dedicated to improving the lives of patients through the
discovery, development and commercialization of novel drugs for
acute cardiovascular disease, cancer and other debilitating medical
conditions. Nuvelo's development pipeline includes NU172, a direct
thrombin inhibitor which has completed Phase 1 development for use
as a potential short-acting anticoagulant during medical or
surgical procedures; and NU206, a Wnt pathway modulator in Phase 1
development for the potential treatment of chemotherapy/radiation
therapy-induced mucositis and inflammatory bowel disease. In
addition, Nuvelo is pursuing research programs in leukemia and
lymphoma therapeutic antibodies and Wnt signaling pathway
therapeutics to further expand its pipeline and create additional
partnering and licensing opportunities. Information about Nuvelo is
available at its website at http://www.nuvelo.com/ or by phoning
650-517-8000. Forward-looking statements This press release
contains "forward-looking statements" which include, without
limitation, statements regarding the completion of the proposed
merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub,
Inc., the transaction's anticipated completion and the progress of
the companies' clinical stage and research programs, which
statements are hereby identified as "forward-looking statements"
for purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
companies' managements' current expectations and involve risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward- looking statements
as a result of many factors, including, without limitation, failure
of Nuvelo's stockholders to approve an amendment to Nuvelo's
certificate of incorporation to effect a reverse stock split, which
is a necessary condition to completion of the proposed merger, the
ability to complete the proposed merger in a timely fashion, the
risk that Nuvelo's and ARCA's business operations will not be
integrated successfully; the combined company's inability to
further identify, develop and achieve commercial success for
products and technologies; the risk that the combined company's
financial resources will be insufficient to meet the combined
company's business objectives; uncertainties relating to drug
discovery and the regulatory approval process; clinical development
processes; enrollment rates for patients in the companies' clinical
trials; changes in relationships with strategic partners and
dependence upon strategic partners for the performance of critical
activities under collaborative agreements; and the impact of
competitive products and technological changes. These and other
factors are identified and described in more detail in Nuvelo's
filings with the SEC, including without limitation Nuvelo's
quarterly report on Form 10-Q for the quarter ended September 30,
2008 and subsequent filings. Nuvelo and ARCA disclaim any intent or
obligation to update these forward-looking statements. Additional
Information and Where to Find It Nuvelo has filed a registration
statement on Form S-4, and a related proxy
statement/prospectus/consent solicitation, together with related
supplemental information, in connection with the merger. Investors
and security holders are urged to read the registration statement
on Form S-4 and the related proxy statement/prospectus/consent
solicitation, as supplemented, because they contain important
information about the merger transaction. Investors and security
holders may obtain free copies of these documents and other
documents filed with the SEC at the SEC's website at
http://www.sec.gov/. In addition, investors and security holders
may obtain free copies of the documents filed with the SEC by
contacting Nuvelo Investor Relations at the email address: or by
phone at 650-517-8000. In addition to the registration statement
and related proxy statement/prospectus/consent solicitation, Nuvelo
files annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any reports,
statements or other information filed by Nuvelo, Inc. at the SEC
public reference room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for more information.
Please call the SEC at 1-800-SEC-0330 for further information on
the public reference room. Nuvelo, Inc.'s filings with the SEC are
also available to the public from commercial document-retrieval
services and at SEC's website at http://www.sec.gov/, and from
Investor Relations at Nuvelo as described above. This communication
shall not constitute an offer to sell or the solicitation of an
offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the Securities Act of 1933, as
amended. Nuvelo, ARCA and their respective directors and executive
officers may be deemed to be participants in the solicitation of
proxies from the stockholders of Nuvelo in connection with the
merger transaction. Information regarding the special interests of
these directors and executive officers in the merger transaction is
included in the proxy statement/prospectus/consent solicitation
described above, as supplemented. Additional information regarding
the directors and executive officers of Nuvelo is also included in
Nuvelo's proxy statement for its 2008 Annual Meeting of
Stockholders which was filed with the SEC on April 23, 2008 and its
Annual Report on Form 10-K for the year ended December 31, 2007,
which was filed with the SEC on March 12, 2008. These documents are
available as described above. DATASOURCE: ARCA biopharma, Inc. and
Nuvelo, Inc CONTACT: Greg Gin of Invigorate Communications,
+1-908-376-7737, ; or Danielle Bertrand of WeissComm Partners,
+1-415-946-1056, Web Site: http://www.arcabiopharma.com/
http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From May 2024 to Jun 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2023 to Jun 2024